An exploratory study of administration of foscarnet for cytomegalovirus infection and human herpes virus type 6 infection after hematopoietic stem cell transplantation..

An exploratory study of administration of foscarnet for cytomegalovirus infection and human herpes virus type 6 infection after hematopoietic stem cell transplantation.. - Foscarnet for CMV and HHV6 infection after HSCT.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003041

Enrollment

Registered

2010-01-20

Start date

2010-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cytomegalovirus infection and human herpes virus type 6 infection after hematopoietic stem cell transplantation

Interventions

Intravenous administration of foscarnet. Induction: 90mg/kg, twice a day. Maintenance: 90mg/kg, once a day.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who have received hematopoietic stem cell transplantation 2. Patients with cytomegalovirus infection or human herpes virus type 6 infection.

Exclusion criteria

Exclusion criteria: 1. Allergy to foscarnet. 2. The creatinine clearance is less than 0.4mL/min/kg. 3. HIV-positive patients. 4. A woman during pregnancy or potential pregnancy. 5. Patients who are recognized as inadaptable for this trial.

Design outcomes

Primary

Measure	Time frame
Changes in viral load at the end of treatment.	—

Secondary

Measure	Time frame
Changes in the symptoms of viral infection at the end of treatment. Survival at two months after the end of treatment. Re-administration of antiviral drugs within two months after the end of treatment. Adverse events.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026